MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2018-07-17 for PROPEL CONTOUR SINUS IMPLANT 50011 manufactured by Intersect Ent.
[114280633]
This patient had pre-existing history of a csf leak in the same location that had stopped spontaneously and that may have pre-disposed him for a csf leak. The treating physician does not believe the implants caused the csf leak. The cause of the csf leak is unknown. The relationship of the presence of the implants and reported event could not be confirmed. Intersect ent believes the event was not device-related. The event is being reported to be conservative. The sinus implant is intended for use in patients greater than or equal to 18 years of age to maintain patency of the frontal and maxillary sinus ostia following sinus surgery and locally deliver steroids to the sinus mucosa. The sinus implant separates/dilates mucosal tissues, prevents obstruction by adhesions/scarring, and reduces edema. The implant reduces the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids. Product instructions for use provide adequate directions. No issues were reported with the delivery system. The implant was deployed successfully. Risks associated with the use of this sinus implant are anticipated to be similar to those experienced by patients who undergo placement of other sinus implants or packing. Manifestation of a csf leak is a known potential surgical complication and may occur inadvertently due to the insertion of any surgical instrument. Patients weight, ethnicity and race are unknown. The following is being provided as this device is a combination product: name: propel mini. Dose, frequency & route used: 370 ug; drug eluting implant placed during surgery; intra-sinal. Diagnosis for use (indication): the sinus implant is intended for use in patients greater than or equal to 18 years of age to maintain patency of the frontal sinus ostia following sinus surgery and locally deliver steroids to the sinus mucosa. Lot number is unknown; therefore, the expiration date and udi are unknown. Explant date: at the time of the event implants were in place; unknown if implant(s) were removed at a later date. Refer to mfr report numbers 3008301917-2018-00001, 3008301917-2018-00002, 3008301917-2018-00003 for additional implants placed in the ethmoid and frontal sinuses.
Patient Sequence No: 1, Text Type: N, H10
[114280634]
The physician reported a csf leak during the first follow-up visit approximately 1 week following a sinus surgery that included placement of four sinus implants bilaterally in the recess of the frontal and ethmoid sinuses. The surgery was a bilateral revision fess that included polypectomy and balloon sinuplasty. This patient had previously undergone multiple sinus surgeries for removal of mucosal polyps (dates unknown). During placement of the implants the physician observed that the amount of surrounding bone was minimal and the dura was still compromised from previous surgeries. The physician reported they were not overly aggressive with the microdebrider and had ballooned both frontal sinuses with a guided system. The leak was not observed immediately following surgery. During the first follow-up visit (1 week post-op), patient complained of headaches and clear fluid drainage. The leak was observed by endoscopic examination and reported to be coming from the left ethmoid cavity. The physician described the dura as wet but not torn; the physician maintained the patient on oral antibiotics and bedrest. The implant was visible and not disturbed. At a subsequent visit (b)(6) 2018 the csf leak had not resolved and the patient was referred to another physician for endoscopic closure of the csf leak. It was reported that the patient has recovered and has had no further issues.
Patient Sequence No: 1, Text Type: D, B5
| Report Number | 3008301917-2018-00004 |
| MDR Report Key | 7697204 |
| Report Source | COMPANY REPRESENTATIVE,HEALTH |
| Date Received | 2018-07-17 |
| Date of Report | 2018-06-18 |
| Date of Event | 2018-04-26 |
| Date Mfgr Received | 2018-06-18 |
| Date Added to Maude | 2018-07-17 |
| Event Key | 0 |
| Report Source Code | Manufacturer report |
| Manufacturer Link | Y |
| Number of Patients in Event | 0 |
| Adverse Event Flag | 3 |
| Product Problem Flag | 3 |
| Reprocessed and Reused Flag | 3 |
| Health Professional | 3 |
| Initial Report to FDA | 3 |
| Report to FDA | 3 |
| Event Location | 3 |
| Manufacturer Contact | MRS AMY WOLBECK |
| Manufacturer Street | 1555 ADAMS DR |
| Manufacturer City | MENLO PARK CA 94025 |
| Manufacturer Country | US |
| Manufacturer Postal | 94025 |
| Manufacturer G1 | INTERSECT ENT |
| Manufacturer Street | 1555 ADAMS DR |
| Manufacturer City | MENLO PARK CA 94025 |
| Manufacturer Country | US |
| Manufacturer Postal Code | 94025 |
| Single Use | 3 |
| Previous Use Code | 3 |
| Event Type | 3 |
| Type of Report | 3 |
| Brand Name | PROPEL CONTOUR SINUS IMPLANT |
| Generic Name | DRUG ELUTING SINUS STENT |
| Product Code | OWO |
| Date Received | 2018-07-17 |
| Model Number | 50011 |
| Operator | HEALTH PROFESSIONAL |
| Device Availability | N |
| Device Eval'ed by Mfgr | N |
| Device Sequence No | 1 |
| Device Event Key | 0 |
| Manufacturer | INTERSECT ENT |
| Manufacturer Address | 1555 ADAMS DR MENLO PARK CA 94025 US 94025 |
| Patient Number | Treatment | Outcome | Date |
|---|---|---|---|
| 1 | 0 | 1. Required No Informationntervention | 2018-07-17 |